

Eukarÿs semi-finalist of the Merck-Millipore's European Advance Biotech Competition



Evry-Courcouronnes, Saturday March 14, 2020,

Eukarÿs is pleased to announce be semi-finalist of the 2020 European Competition Advance Biotech Grant Program organized by the Merck-Millipore..

This is part of the effort to produce synthetic DNA, on which the synthetic gene therapy developed by Eukarÿs is based.

About Eukarÿs:

Eukarÿs is a French biotechnology company from the Biocluster of the Genopole of Evry which is developing a radically innovative non-viral approach to synthetic gene therapy. It is designed to be usable for the majority of human diseases and to provide solutions to the challenges of safety, tolerance, immunogenicity and production costs which gene therapy must face.

Synthetic gene therapy uses the first, and to date the only, eukaryotic artificial expression system called C3P3 invented and patented by Eukarÿs.

Contact: Eukarÿs SAS | Genopole Campus 3 | 4 rue Pierre Fontaine | 91000 Evry-Courcouronnes, France | contact@eukarys.com | www.eukarys.com